Effects of the SGLT2 Inhibitor Dapagliflozin on Energy Metabolism in Patients With Type 2 Diabetes: A Randomized, Double-Blind Crossover Trial

被引:40
|
作者
Op den Kamp, Yvo J. M. [1 ]
de Ligt, Marlies [1 ]
Dautzenberg, Bas [1 ]
Kornips, Esther [1 ]
Esterline, Russell [2 ]
Hesselink, Matthijs K. C. [1 ]
Hoeks, Joris [1 ]
Schrauwen-Hinderling, Vera B. [1 ,3 ]
Havekes, Bas [4 ]
Oscarsson, Jan [5 ]
Phielix, Esther [1 ]
Schrauwen, Patrick [1 ]
机构
[1] Maastricht Univ, NUTRIM Sch Nutr & Translat Res Metab, Dept Nutr & Movement Sci, Med Ctr, Maastricht, Netherlands
[2] AstraZeneca, BioPharmaceut R&D, Gaithersburg, MD USA
[3] Maastricht Univ, Radiol & Nucl Med, Med Ctr, Maastricht, Netherlands
[4] Maastricht Univ, Internal Med, Med Ctr, Maastricht, Netherlands
[5] AstraZeneca, BioPharmaceut R&D, Late Stage Dev Cardiovasc Renal & Metab, Gothenburg, Sweden
关键词
INSULIN SENSITIVITY; RESPIRATION CHAMBER; SECRETION; MEN;
D O I
10.2337/dc20-2887
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVE SGTL2 inhibitors increase urinary glucose excretion and have beneficial effects on cardiovascular and renal outcomes. The underlying mechanism may involve caloric restriction-like metabolic effects due to urinary glucose loss. We investigated the effects of dapagliflozin on 24-h energy metabolism and insulin sensitivity in patients with type 2 diabetes. RESEARCH DESIGN AND METHODS There were 26 patients with type 2 diabetes randomized to a 5-week double-blind, crossover study with a 6- to 8-week washout. Indirect calorimetry was used to measure 24-h energy metabolism and the respiratory exchange ratio (RER), both by whole-room calorimetry and by ventilated hood during a two-step euglycemic-hyperinsulinemic clamp. Results are presented as the differences in least squares mean (95% CI) between treatments. RESULTS Evaluable patients (n = 24) had a mean (SD) age of 64.2 (4.6) years, BMI of 28.1 (2.4) kg/m(2), and HbA(1c) of 6.9% (0.7) (51.7 [6.8] mmol/mol). Rate of glucose disappearance was unaffected by dapagliflozin, whereas fasting endogenous glucose production (EGP) increased by dapagliflozin (+2.27 [1.39, 3.14] mu mol/kg/min, P < 0.0001). Insulin-induced suppression of EGP (-1.71 [-2.75, -0.63] mu mol/kg/min, P = 0.0036) and plasma free fatty acids (-21.93% [-39.31, -4.54], P = 0.016) was greater with dapagliflozin. Twenty-four-hour energy expenditure (-0.11 [-0.24, 0.03] MJ/day) remained unaffected by dapagliflozin, but dapagliflozin reduced the RER during daytime and nighttime, resulting in an increased day-to-nighttime difference in the RER (-0.010 [-0.017, -0.002], P = 0.016). Dapagliflozin treatment resulted in a negative 24-h energy and fat balance (-20.51 [-27.90, -13.12] g/day). CONCLUSIONS Dapagliflozin treatment for 5 weeks resulted in major adjustments of metabolism mimicking caloric restriction, increased fat oxidation, improved hepatic and adipose insulin sensitivity, and improved 24-h energy metabolism.
引用
收藏
页码:1334 / 1343
页数:10
相关论文
共 50 条
  • [21] RENOPROTECTIVE EFFECT OF SGLT2 INHIBITOR DAPAGLIFLOZIN IN TYPE-1 DIABETES
    Balogh, Dora
    Hodrea, Judit
    Lenart, Lilla
    Hosszu, Adam
    Szkibinszkij, Edgar
    Vannay, Adam
    Wagner, Laszlo
    Szabo, Attila
    Fekete, Andrea
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2017, 32
  • [22] Treatment Effect of the SGLT2 Inhibitor Empagliflozin on Chronic Syndrome of Inappropriate Antidiuresis: Results of a Randomized, Double-Blind, Placebo-Controlled, Crossover Trial
    Refardt, Julie
    Imber, Cornelia
    Nobbenhuis, Rianne
    Sailer, Clara O.
    Haslbauer, Aaron
    Monnerat, Sophie
    Bathelt, Cemile
    Vogt, Deborah R.
    Berres, Manfred
    Winzeler, Bettina
    Bridenbaugh, Stephanie A.
    Christ-Crain, Mirjam
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2023, 34 (02): : 322 - 332
  • [23] Effects of the SGLT2 inhibitor dapagliflozin on cardiac function evaluated by impedance cardiography in patients with type 2 diabetes. Secondary analysis of a randomized placebo-controlled trial
    Bonora, Benedetta Maria
    de Kreutzenberg, Saula Vigili
    Avogaro, Angelo
    Fadini, Gian Paolo
    CARDIOVASCULAR DIABETOLOGY, 2019, 18 (01)
  • [24] Effects of the SGLT2 inhibitor dapagliflozin on cardiac function evaluated by impedance cardiography in patients with type 2 diabetes. Secondary analysis of a randomized placebo-controlled trial
    Benedetta Maria Bonora
    Saula Vigili de Kreutzenberg
    Angelo Avogaro
    Gian Paolo Fadini
    Cardiovascular Diabetology, 18
  • [25] Effects of the SGLT2 inhibitor dapagliflozin on cardiac function evaluated by impedance cardiography in patients with type 2 diabetes: a randomised placebo-controlled trial
    de Kreutzenberg, S. Vigili
    Bonora, B. M.
    Avogaro, A.
    Fadini, G.
    DIABETOLOGIA, 2019, 62 : S327 - S327
  • [26] THE SGLT2 INHIBITOR DAPAGLIFLOZIN IMPROVES ERECTILE DYSFUNCTION IN PATIENTS WITH TYPE 2 DIABETES MELLITUS: A PROSPECTIVE STUDY
    Cannarella, Rossella
    Condorelli, Rosita A. Angela
    Leanza, Claudia
    Garofalo, Vincenzo
    Lundy, Scott
    Calogero, Aldo E.
    La Vignera, Sandro
    FERTILITY AND STERILITY, 2023, 120 (04) : E245 - E246
  • [27] Effect of the SGLT2 Inhibitor Dapagliflozin on Potassium Levels in Patients with Type 2 Diabetes Mellitus: A Pooled Analysis
    Yshai Yavin
    Traci A. Mansfield
    Agata Ptaszynska
    Kristina Johnsson
    Shamik Parikh
    Eva Johnsson
    Diabetes Therapy, 2016, 7 : 125 - 137
  • [28] Effect of the SGLT2 Inhibitor Dapagliflozin on Potassium Levels in Patients with Type 2 Diabetes Mellitus: A Pooled Analysis
    Yavin, Yshai
    Mansfield, Traci A.
    Ptaszynska, Agata
    Johnsson, Kristina
    Parikh, Shamik
    Johnsson, Eva
    DIABETES THERAPY, 2016, 7 (01) : 125 - 137
  • [29] Dapagliflozin, a selective SGLT2 inhibitor, has a low propensity to cause hypoglycaemia in patients with type 2 diabetes
    Rohwedder, K.
    Hrub, V.
    Salsali, A.
    Ying, L.
    Sugg, J.
    List, J. F.
    Parikh, S.
    DIABETOLOGIA, 2011, 54 : S348 - S349
  • [30] Dapagliflozin, a selective SGLT2 inhibitor, reduces serum levels of uric acid in patients with type 2 diabetes
    Hardy, E.
    Rohwedder, K.
    Hrub, V.
    Salsali, A.
    Ying, L.
    Sugg, J.
    List, J. F.
    Parikh, S.
    DIABETOLOGIA, 2011, 54 : S344 - S345